| Methods |
Design:
randomized, placebo‐ controlled, double blind
parallel groups
8 weeks |
| Participants |
Country: U.S.A.
n=14 (12 completers) probable AD NINCDS/ADRDA, mild‐moderate dementia (MMSE: 17‐25), not institutionalised. Aged 79 (SD 8, 77‐85 yrs). Exclusion criteria: medical, neurological or psychiatric disease. HRT or cognition enhancer use last for the 2 months. Natural menopause ? (all underwent pap smears) |
| Interventions |
1. E2 transdermal 0.05 mg
2. Placebo |
| Outcomes |
General (MMSE, BIMC)
Memory: (BSRT, VRT, Paragraph recall)
Speed (Stroop, TMT), Language: Fluency (letter), Token test |
| Notes |
HRT > placebo: on BSRT, Stroop (trends for VRT & Token test) 4/9 test
Adverse events:
1 drop‐out due to skin irritations |
